Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. / Friis-Møller, Nina; Thiébaut, Rodolphe; Reiss, Peter; Weber, Rainer; Monforte, Antonella D'arminio; De Wit, Stephane; El-Sadr, Wafaa; Fontas, Eric; Worm, Signe; Kirk, Ole; Phillips, Andrew; Sabin, Caroline A; Lundgren, Jens; Law, Matthew G; for the DAD study group; Friis-Møller, Nina; Thiébaut, Rodolphe; Reiss, Peter; Weber, Rainer; Monforte, Antonella D'Arminio; De Wit, Stephane; El-Sadr, Wafaa; Fontas, Eric; Worm, Signe Westring; Kirk, Ole; Phillips, Andrew; Sabin, Caroline A; Law, Matthew G; DAD study group.
I: European Journal of Cardiovascular Prevention & Rehabilitation, Bind 17, Nr. 5, 01.10.2010, s. 491-501.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study
AU - Friis-Møller, Nina
AU - Thiébaut, Rodolphe
AU - Reiss, Peter
AU - Weber, Rainer
AU - Monforte, Antonella D'arminio
AU - De Wit, Stephane
AU - El-Sadr, Wafaa
AU - Fontas, Eric
AU - Worm, Signe
AU - Kirk, Ole
AU - Phillips, Andrew
AU - Sabin, Caroline A
AU - Lundgren, Jens
AU - Law, Matthew G
AU - for the DAD study group
AU - Friis-Møller, Nina
AU - Thiébaut, Rodolphe
AU - Reiss, Peter
AU - Weber, Rainer
AU - Monforte, Antonella D'Arminio
AU - De Wit, Stephane
AU - El-Sadr, Wafaa
AU - Fontas, Eric
AU - Worm, Signe Westring
AU - Kirk, Ole
AU - Phillips, Andrew
AU - Sabin, Caroline A
AU - Law, Matthew G
AU - DAD study group
PY - 2010/10/1
Y1 - 2010/10/1
N2 - AIMS: HIV-infected patients receiving combination antiretroviral therapy may experience metabolic complications, potentially increasing their risk of cardiovascular diseases (CVDs). Furthermore, exposures to some antiretroviral drugs seem to be independently associated with increased CVD risk. We aimed to develop cardiovascular risk-assessment models tailored to HIV-infected patients. METHODS AND RESULTS: Prospective multinational cohort study. The data set included 22 625 HIV-infected patients from 20 countries in Europe and Australia who were free of CVD at entry into the Data collection on Adverse Effects of Anti-HIV Drugs Study. Using cross-validation methods, separate models were developed to predict the risk of myocardial infarction, coronary heart disease, and a composite CVD endpoint. Model performance was compared with the Framingham score.The models included age, sex, systolic blood pressure, smoking status, family history of CVD, diabetes, total cholesterol, HDL cholesterol and indinavir, lopinavir/r and abacavir exposure. The models performed well with area under the receiver operator curve statistics of 0.783 (range 0.642-0.820) for myocardial infarction, 0.776 (0.670-0.818) for coronary heart disease and 0.769 (0.695-0.824) for CVD. The models estimated more accurately the outcomes in the subgroups than the Framingham score. CONCLUSION: Risk equations developed from a population of HIV-infected patients, incorporating routinely collected cardiovascular risk parameters and exposure to individual antiretroviral therapy drugs, might be more useful in estimating CVD risks in HIV-infected persons than conventional risk prediction models.
AB - AIMS: HIV-infected patients receiving combination antiretroviral therapy may experience metabolic complications, potentially increasing their risk of cardiovascular diseases (CVDs). Furthermore, exposures to some antiretroviral drugs seem to be independently associated with increased CVD risk. We aimed to develop cardiovascular risk-assessment models tailored to HIV-infected patients. METHODS AND RESULTS: Prospective multinational cohort study. The data set included 22 625 HIV-infected patients from 20 countries in Europe and Australia who were free of CVD at entry into the Data collection on Adverse Effects of Anti-HIV Drugs Study. Using cross-validation methods, separate models were developed to predict the risk of myocardial infarction, coronary heart disease, and a composite CVD endpoint. Model performance was compared with the Framingham score.The models included age, sex, systolic blood pressure, smoking status, family history of CVD, diabetes, total cholesterol, HDL cholesterol and indinavir, lopinavir/r and abacavir exposure. The models performed well with area under the receiver operator curve statistics of 0.783 (range 0.642-0.820) for myocardial infarction, 0.776 (0.670-0.818) for coronary heart disease and 0.769 (0.695-0.824) for CVD. The models estimated more accurately the outcomes in the subgroups than the Framingham score. CONCLUSION: Risk equations developed from a population of HIV-infected patients, incorporating routinely collected cardiovascular risk parameters and exposure to individual antiretroviral therapy drugs, might be more useful in estimating CVD risks in HIV-infected persons than conventional risk prediction models.
U2 - 10.1097/HJR.0b013e328336a150
DO - 10.1097/HJR.0b013e328336a150
M3 - Journal article
C2 - 20543702
VL - 17
SP - 491
EP - 501
JO - European Journal of Preventive Cardiology
JF - European Journal of Preventive Cardiology
SN - 2047-4873
IS - 5
ER -
ID: 20445169